JP2017527550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527550A5 JP2017527550A5 JP2017508482A JP2017508482A JP2017527550A5 JP 2017527550 A5 JP2017527550 A5 JP 2017527550A5 JP 2017508482 A JP2017508482 A JP 2017508482A JP 2017508482 A JP2017508482 A JP 2017508482A JP 2017527550 A5 JP2017527550 A5 JP 2017527550A5
- Authority
- JP
- Japan
- Prior art keywords
- autotaxin inhibitor
- inhibitor according
- individual
- autotaxin
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 24
- 230000002401 inhibitory effect Effects 0.000 claims 24
- 102100016621 ENPP2 Human genes 0.000 claims 20
- 101700057276 ENPP2 Proteins 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 9
- 210000004369 Blood Anatomy 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 229940079593 drugs Drugs 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 229920000023 polynucleotide Polymers 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 229940107161 Cholesterol Drugs 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008338 Non-alcoholic Fatty Liver Disease Diseases 0.000 claims 2
- 108009000135 Nonalcoholic fatty liver disease Proteins 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 241001553178 Arachis glabrata Species 0.000 claims 1
- 229940030609 CALCIUM CHANNEL BLOCKERS Drugs 0.000 claims 1
- 208000008787 Cardiovascular Disease Diseases 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 229940030606 DIURETICS Drugs 0.000 claims 1
- 102100003818 GCG Human genes 0.000 claims 1
- 101710042131 GCG Proteins 0.000 claims 1
- 208000004104 Gestational Diabetes Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 102000036849 Islet amyloid polypeptide Human genes 0.000 claims 1
- 108010041872 Islet amyloid polypeptide Proteins 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010053219 Non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 102000035443 Peptidases Human genes 0.000 claims 1
- 108091005771 Peptidases Proteins 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 102000000070 Sodium-Glucose Transport Proteins Human genes 0.000 claims 1
- 108010080361 Sodium-Glucose Transport Proteins Proteins 0.000 claims 1
- 229940090121 Sulfonylureas for blood glucose lowering Drugs 0.000 claims 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 230000001396 anti-anti-diuretic Effects 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940058933 biguanide antimalarials Drugs 0.000 claims 1
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 229940090127 blood glucose lowering Alpha glucosidase inhibitors Drugs 0.000 claims 1
- 229940090129 blood glucose lowering drugs Thiazolidinediones Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 230000001112 coagulant Effects 0.000 claims 1
- 239000000701 coagulant Substances 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 235000020828 fasting Nutrition 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000002452 interceptive Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000036454 renin-angiotensin system Effects 0.000 claims 1
- 230000000580 secretagogue Effects 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
Claims (15)
- 代謝障害の個体の血糖値を下げるのに使用するためのオートタキシン阻害剤。
- 個体における血糖値は前記オートタキシン阻害剤の投与後に少なくとも10%下がる、請求項1に記載のオートタキシン阻害剤。
- 前記個体における血中のリゾホスファチジン酸(LPA)レベルは、前記オートタキシン阻害剤の投与後に少なくとも20%下がる、請求項1に記載のオートタキシン阻害剤。
- オートタキシン阻害剤は、タンパク質薬、ペプチド薬、ポリペプチド薬、ペプチド模倣薬、抗体薬、小分子薬、低分子干渉RNAコード化ポリヌクレオチド、アンチセンスRNAコード化ポリヌクレオチド、またはリボザイムコード化ポリヌクレオチドからなる群から選択される薬剤である、請求項1に記載のオートタキシン阻害剤。
- オートタキシン阻害剤は、インドール含有小分子である小分子である、請求項1に記載のオートタキシン阻害剤。
- 個体は血糖値が上昇している、請求項1に記載のオートタキシン阻害剤。
- 個体の血糖値は、前記オートタキシン阻害剤の投与前、100mg/dLよりも高い、請求項1に記載のオートタキシン阻害剤。
- 個体はメタボリック症候群を抱えている、請求項1乃至7の何れか1つに記載のオートタキシン阻害剤。
- 個体は、腹部肥満、高血圧、空腹時の高血漿グルコース、高血清トリグリセリド、および低い高密度コレステロールレベル(HDL)からなる群から選択される少なくとも1つの医学的状態を抱えている、請求項1乃至7の何れか1つに記載のオートタキシン阻害剤。
- 個体はインスリン抵抗性、2型糖尿病、少なくとも6.0%以上のA1Cレベルを有し、非アルコール性脂肪肝疾患(NAFLD)、または非アルコール性の脂肪性肝炎と診断されたことがあり、耐糖能障害を抱えており、且つ前糖尿病性である、請求項1乃至7の何れか1つに記載のオートタキシン阻害剤。
- 個体は、少なくとも25kg/m 2 の肥満度指数を有するとともに、運動不足、糖尿病の一等親血縁者、リスクの高い人種または民族性、4.08キログラムを超える重さの赤ん坊を出産した女性、以前に妊娠性糖尿病と診察されたことがある女性、高血圧、少なくとも0.9mmol/L(35mg/dL)よりも低いHDLコレステロールレベル、少なくとも2.82mmol/L(250mg/dL)以上のトリグリセリドレベル、多嚢胞性卵巣症候群、重度の肥満、黒色表皮腫、および心血管疾患の女性からなる群から選択される糖尿病の危険因子の少なくとも1つ以上を有する、請求項1乃至7の何れか1つに記載のオートタキシン阻害剤。
- 個体は肥満である、請求項1乃至7の何れか1つに記載のオートタキシン阻害剤。
- 追加の治療薬をさらに含む、血糖値を下げるのに使用するための請求項1乃至7の何れか1つに記載のオートタキシン阻害剤。
- 追加の治療薬は、ペルオキシソーム増殖因子活性化受容体(PPAR)アゴニスト(ガンマ、デュアル、またはパン)、ジペプチジルペプチダーゼ(IV)阻害剤、グルカゴン様ペプチド−1(GLP−I)アナログ、インスリンまたはインスリンアナログ、インスリン分泌促進物質、ナトリウムグルコース共輸送体2(SGLT2)阻害剤、ヒトアミリンアナログ、ビグアニド、グルコファージ、アルファ−グルコシダーゼ阻害剤、メグリチニド、チアゾリジンジオン、およびスルホニル尿素、またはこれらの任意の組み合わせからなる群から選択される、請求項13に記載のオートタキシン阻害剤。
- 追加の治療薬は、アンジオテンシン変換酵素(ACE)阻害剤、アンジオテンシンII受容体拮抗薬(ARB)、β−遮断薬、利尿薬、カルシウムチャネル遮断薬、レニン−アンジオテンシン系(RAS)の阻害剤、抗凝血薬、スタチン、および、フィブラート系薬剤、または、これらの任意の組み合わせからなる群から選択される、請求項13に記載のオートタキシン阻害剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/462,459 | 2014-08-18 | ||
US14/462,459 US9051320B1 (en) | 2014-08-18 | 2014-08-18 | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
PCT/US2015/045518 WO2016028686A1 (en) | 2014-08-18 | 2015-08-17 | Methods and compositions for the treatment of metabolic disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017527550A JP2017527550A (ja) | 2017-09-21 |
JP2017527550A5 true JP2017527550A5 (ja) | 2018-09-27 |
JP6817190B2 JP6817190B2 (ja) | 2021-01-20 |
Family
ID=53267810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017508482A Active JP6817190B2 (ja) | 2014-08-18 | 2015-08-17 | 代謝障害の処置のための方法と組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9051320B1 (ja) |
EP (1) | EP3183005A4 (ja) |
JP (1) | JP6817190B2 (ja) |
WO (1) | WO2016028686A1 (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3046905A4 (en) | 2013-09-17 | 2017-03-22 | Pharmakea Inc. | Vinyl autotaxin inhibitor compounds |
JP2016530210A (ja) | 2013-09-17 | 2016-09-29 | ファーマケア,インク. | ヘテロ環式ビニルオートタキシン阻害剤化合物 |
US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
AU2014352887A1 (en) | 2013-11-22 | 2016-06-09 | Pharmakea, Inc. | Tetracyclic autotaxin inhibitors |
AU2014352888B2 (en) | 2013-11-22 | 2019-05-09 | Sabre Therapeutics Llc | Autotaxin inhibitor compounds |
US9051320B1 (en) * | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
US10183949B2 (en) * | 2014-08-29 | 2019-01-22 | The University Of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
EP3265456B1 (en) | 2015-03-06 | 2020-11-18 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
EP4026549A1 (en) * | 2015-05-27 | 2022-07-13 | Sabre Therapeutics LLC | Autotaxin inhibitors and uses thereof |
CA2987071A1 (en) | 2015-06-10 | 2016-12-15 | Hackensack University Medical Center | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases |
ES2870030T3 (es) * | 2015-10-30 | 2021-10-26 | Univ Muenster Westfaelische Wilhelms | Reducción del nivel de LPA para tratar trastornos del sistema nervioso central |
CA3033863C (en) * | 2016-08-18 | 2021-09-14 | Memorial Sloan Kettering Cancer Center | Inhibition of sphingosine 1-phosphate receptor for treatment and prevention of lymphedema |
EA201990621A1 (ru) | 2016-09-07 | 2019-09-30 | Фармакеа, Инк. | Кристаллические формы ингибитора лизилоксидаза-подобного белка 2 и способы получения |
KR102615565B1 (ko) | 2016-09-07 | 2023-12-18 | 파마케아, 인크. | 리실 옥시다제 유사 2 억제제의 용도 |
CN106822114B (zh) * | 2016-12-12 | 2020-08-07 | 中国科学院西北高原生物研究所 | Mtca在制备降血糖或降血脂的药物中的用途 |
JP2021528738A (ja) * | 2018-06-14 | 2021-10-21 | アストラゼネカ・ユーケイ・リミテッドAstraZeneca UK Limited | メトホルミン医薬組成物を用いて血糖を低下させるための方法 |
EP3807893A1 (en) * | 2018-06-14 | 2021-04-21 | AstraZeneca UK Limited | Methods for lowering blood sugar with a gliflozin sodium-glucose cotransporter 2 inhibitor pharmaceutical composition |
GR1010570B (el) | 2022-12-22 | 2023-11-17 | Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., | 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης |
CN116239577A (zh) * | 2023-03-27 | 2023-06-09 | 沈阳药科大学 | 一种制备Cudetaxestat的方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210574A (en) | 1991-03-08 | 1993-05-11 | Mita Industrial Co., Ltd. | Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum |
US5186522A (en) | 1991-09-24 | 1993-02-16 | Midland Brake, Inc. | Air dryer purge line |
KR940703981A (ko) | 1992-11-10 | 1994-12-12 | 존 에이취. 롱 | 솔레노이드 밸브 조립체(Solenoid valve assembly) |
US5407368A (en) | 1992-12-15 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Electrode connector |
US5761473A (en) | 1993-01-08 | 1998-06-02 | International Business Machines Corporation | Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking |
US5564949A (en) | 1995-01-05 | 1996-10-15 | Thomas & Betts Corporation | Shielded compact data connector |
JP2664048B2 (ja) | 1995-03-27 | 1997-10-15 | 科学技術庁金属材料技術研究所長 | 六フッ化二ケイ素の合成法 |
JP4714143B2 (ja) | 2004-05-19 | 2011-06-29 | 住友電気工業株式会社 | Iii族窒化物半導体結晶の製造方法 |
KR101141650B1 (ko) | 2004-09-30 | 2012-05-17 | 엘지전자 주식회사 | 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말 |
US20060270634A1 (en) | 2005-05-06 | 2006-11-30 | Miller Duane D | Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors |
US7921385B2 (en) | 2005-10-03 | 2011-04-05 | Luminescent Technologies Inc. | Mask-pattern determination using topology types |
CA2690762C (en) | 2007-06-15 | 2016-06-14 | Glenn Prestwich | .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof |
DE102007047735A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Thiazolderivate |
DE102007047738A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
US8268891B1 (en) | 2007-11-13 | 2012-09-18 | University Of Memphis Research Foundation | Autotaxin inhibitors |
US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
US8022239B2 (en) | 2008-10-03 | 2011-09-20 | The University Of Memphis Research Foundation | Mechanism-based inactivators of autotaxin |
DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
KR20110093923A (ko) | 2008-12-01 | 2011-08-18 | 메르크 파텐트 게엠베하 | 암에 대한 오토탁신 저해제로서의 2,5-디아미노-치환된 피리도 [4,3-d]피리미딘 |
CA2757413C (en) | 2009-04-02 | 2017-01-10 | Merck Patent Gmbh | Heterocyclic compounds as autotaxin inhibitors |
ES2880623T3 (es) | 2009-04-02 | 2021-11-25 | Merck Patent Gmbh | Derivados de piperidina y piperazina como inhibidores de autotaxina |
US8329907B2 (en) | 2009-04-02 | 2012-12-11 | Merck Patent Gmbh | Autotaxin inhibitors |
JP2012526828A (ja) | 2009-05-11 | 2012-11-01 | バーグ バイオシステムズ,エルエルシー | エピメタボリックシフター、多次元細胞内分子、または環境影響因子を使用する代謝性障害の治療方法 |
CN102459598B (zh) | 2009-05-20 | 2016-06-01 | Eth苏黎世公司 | 用于代谢紊乱的靶向微小rna |
US8343934B2 (en) | 2009-06-30 | 2013-01-01 | University Of Memphis | Diverse lead compound autotaxin inhibitors |
DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
WO2011053597A1 (en) | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
EP2552914B1 (de) | 2010-03-26 | 2015-11-11 | Merck Patent GmbH | Benzonaphthyridinamine als autotaxin-inhibitoren |
US20130116171A1 (en) | 2010-04-16 | 2013-05-09 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf |
US9000025B2 (en) * | 2010-08-20 | 2015-04-07 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
WO2012054555A2 (en) * | 2010-10-20 | 2012-04-26 | Glycomark, Inc. | Improved identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers |
US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
US8673882B2 (en) | 2011-01-20 | 2014-03-18 | University Of Tennessee Research Foundation | Inhibitors of autotaxin |
EP2714680B1 (en) | 2011-05-27 | 2015-11-25 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
ES2748656T3 (es) | 2011-10-28 | 2020-03-17 | Inhibitaxin Ltd | Derivados de piridazina útiles en terapia |
CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
LT2900669T (lt) | 2012-09-25 | 2019-11-11 | Hoffmann La Roche | Heksahidropirol[3,4-c]pirolo dariniai ir susiję junginai kaip autotaksino (atx) inhibitoriai ir kaip lizofosfatidinės rūgšties (lpa) gamybos inhibitoriai, skirti gydyti pvz., inkstų ligas |
SG11201504633PA (en) | 2012-12-19 | 2015-07-30 | Novartis Ag | Autotaxin inhibitors |
US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
TWI499591B (zh) | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
US9051320B1 (en) * | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
-
2014
- 2014-08-18 US US14/462,459 patent/US9051320B1/en not_active Expired - Fee Related
-
2015
- 2015-08-17 JP JP2017508482A patent/JP6817190B2/ja active Active
- 2015-08-17 EP EP15833802.0A patent/EP3183005A4/en not_active Withdrawn
- 2015-08-17 WO PCT/US2015/045518 patent/WO2016028686A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017527550A5 (ja) | ||
Coskun et al. | LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept | |
Camilleri et al. | Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers | |
Seufert | SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin | |
Donath | Targeting inflammation in the treatment of type 2 diabetes: time to start | |
Bosenberg et al. | The mechanism of action of oral antidiabetic drugs: A review of recent literature | |
AU2019309796B2 (en) | Methods of using a GIP/GLP1 co-agonist for therapy | |
US20170014436A1 (en) | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes. | |
US8697662B2 (en) | Methods for treating Kaposi sarcoma | |
US20170007631A1 (en) | Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D | |
Zhang et al. | Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis | |
JP2020147585A (ja) | 肝臓の疾患を治療するためのオメガ3脂肪酸とsglt−2阻害薬との併用剤 | |
Saroka et al. | SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM | |
Tzotzas et al. | Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of obese women with polycystic ovary syndrome | |
JP2017504649A5 (ja) | ||
JP6878596B2 (ja) | Fxrアゴニストの組合せ | |
JP2021104999A (ja) | Fxrアゴニストの新規のレジーム | |
TW201105336A (en) | Combined medicine of pyrazole derivative and biguanide drug | |
JP2018527374A5 (ja) | ||
JP2013502420A5 (ja) | ||
Ahrens | Antibodies in metabolic diseases | |
Derosa et al. | Efficacy and safety of two dosages of canrenone as add‐on therapy in hypertensive patients taking ace‐inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE‐IT trial | |
CN104001177A (zh) | 一种治疗ii型糖尿病或代谢综合征的复方药物组合物 | |
Johansson et al. | Hyperinsulinemic rats are normotensive but sensitized to angiotensin II | |
Eun et al. | Pheochromocytoma with markedly abnormal liver function tests and severe leukocytosis |